Elena López Miranda

Neoadjuvant and Adjuvant Ribociclib and Endocrine Therapy for Clinically High-risk Estrogen Receptor-positive (ER+) and HER2-negative (HER2-) Breast Cancer

An Open-label Multicenter Phase 1b-2 Study of Elacestrant in Combination with Abemaciclib in Women and Men with Brain Metastasis from Estrogen Receptor Positive, HER-2 Negative Breast Cancer (ELECTRA)

A phase III, randomized, open-label, multicenter study evaluating the efficacy and safety of giredestrant plus everólimus compared with exemestane plus everolimus in patients with estrogen receptor-positive HER”-negative, locally advanced or metastatic breast cancer

Phase Ia/b Study of Giredestrant ±Palbociclib and ±LHRH Agonist in Estrogen Receptor-positive, HER2-negative, Locally Advanced/Metastatic Breast Cancer

A phase 3, multicenter, randomized, open-label, active-controlled study of trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in subjects with high-risk HER2-positive primary breast cancer who have residual invasive disease in breast or axillary lymph nodes following neoadjuvant therapy (DESTINY-Breast05)